Eyevance launches ophthalmic version of cetirizine
Click Here to Manage Email Alerts
ATLANTA – Eyevance announced the U.S. launch of Zerviate, indicated for treating ocular itching associated with allergic conjunctivitis.
The 0.24% cetirizine ophthalmic solution is formulated with Hydrella, a vehicle that contains glycerin and hydroxypropyl methylcellulose, common ingredients found in tear lubricants, the company said in a press release.
Christian Murray, Eyevance director of marketing, told Primary Care Optometry News here at SECO that clinical studies showed that Zerviate, which is available in a single-use vial, had fast onset of action and long duration of effect. She said only one patient in the studies developed dry eye.
The company noted in the release that its national sales force will launch Zerviate through its remote virtual selling platform, offer remote access to co-pay savings and host educational webinars.
Murray shared updates on other Eyevance products with PCON.
Tobradex ST (tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05%), which Eyevance recently launched, is now available nationwide, she said. Murray noted that Alcon is manufacturing the product, as part of a long-term contract with Eyevance.
In this formulation, with the suspension technology called XanGen, the dexamethasone is cut in half, she said, but the residency time is increased.
“Tobramycin was bacteriostatic, but it is now bacteriocidal with the increased residency time,” Murray said. “While instructions are still to shake well, 24 hours after mixing, it has been shown to still have 97% suspension.”
Freshkote Preservative-Free tear lubricant and Flarex (fluorometholone acetate ophthalmic suspension) 0.1% are two other recent launches for Eyevance, Murray said. – by Nancy Hemphill, ELS, FAAO
Disclosure: Murray is employed by Eyevance.
Collapse
Read more about
Click Here to Manage Email Alerts